Certain 5-cyano-16-fluoro-prostacyclins and their use as pharmaceuticals

Abstract

Prostacyclin derivatives of the formula ##STR1## wherein R.sub.1 is OR.sub.3 wherein R.sub.3 is hydrogen or alkyl of 1-10 carbon atoms, or R.sub.1 is NHR.sub.4 wherein R.sub.4 is alkanoyl or alkanesulfonyl, B is alkylene of 1-5 carbon atoms, A is --CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH--, or trans--CH.dbd.CH--, W is hydroxymethylene or ##STR2## wherein the OH-group is optionally substituted by alkanoyl of 1-4 carbon atoms and the free or substituted OH-group can be in the .alpha.- or .beta.- position, R.sub.2 is alkyl of 1-6 carbon atoms optionally substituted by phenyl, or R.sub.2 is phenyl, R.sub.5 is hydroxy optionally substituted by alkanoyl of 1-4 carbon atoms, R.sub.6 is hydrogen, fluorine, or alkyl of 1-4 carbon atoms or when R.sub.3 is hydrogen, a salt thereof with a physiologically compatible base, have pharmacological activity e.g., blood pressure-lowering and bronchodilatory effects.

Dependencies are inferred from the claim text.